Evaluating the Hematological Parameter Alterations Induced by Mavyret in Chronic Hepatitis Patients

Background/Objectives: The hepatitis C virus (HCV) is a significant threat to people with persistent infections. In recent years, the treatment of chronic hepatitis C (CHC) has been transformed significantly with the use of Direct-Acting Antivirals (DAAs). Hematological changes are seen in patients suffering from CHC due to both the disease and its therapy. This study aims to address the gaps in knowledge by thoroughly evaluating the hematological parameter alterations in CHC patients treated with Mavyret. Methods: This study reported that it took place over six months in 2024 on 101 patients observed at the gastroenterology department of Pitesti County Hospital in Romania, who had confirmed diagnoses of CHC and who were receiving the DAA Mavyret. Results: The values of leukocytes significantly decreased after treatment (8.69 ± 2.96 vs. 7.93 ± 1.78, p = 0.009). Similarly, neutrophils showed a statistically significant decrease after using Mavyret (5.45 ± 2.06 vs. 4.91 ± 1.29, p = 0.018). In the case of lymphocytes, the values slightly increased from 2.14 ± 0.69 before treatment to 2.20 ± 1.19 after it, but without a statistically significant difference (p = 0.320). The values of monocytes and eosinophils significantly decreased after antiviral therapy (0.81 ± 1.02 vs. 0.59 ± 0.15, p = 0.020; 0.21 ± 0.15 vs. 0.14 ± 0.09, p < 0.001). For basophils, the mean values remained almost unchanged after DAA therapy (0.09 ± 0.08 vs. 0.09 ± 0.15, p = 0.433). Conclusions: Mavyret has proven to be a safe medication for administering to patients with CHC, but its minor adverse effects on red blood cells, white blood cells, and platelets require constant monitoring, mainly when used for an extended period and in patients who are vulnerable in this regard.